WVE News and Press, Wave Life Sciences Ltd. From 05/11/22

Wave Life Sciences (NASDAQ:WVE) Q1 consensus EPS estimate is -$0.55 and consensus revenue estimate is $3.86M. WVE is scheduled to announce Q1 earnings results on Thursday, May 12, before market open. Over the last 3 months, EPS estimates have seen 4 upward revisions and 0 downw...

Gainers: AxoGen (AXGN) +26%. Better Therapeutics (BTTX) +15%. Intercept Pharmaceuticals (ICPT) +13%. XORTX Therapeutics (XRTX)  +13%. Belite Bio (BLTE) +8%. Losers: Nephros (NEPH) -32%. BioAtla (BCAB) -27%. Outset Medical (OM) -10%. ...

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and confer...

Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional variants and poly(GP) dipeptide repeat proteins in mice for at least six months while maintaining C9orf72 protein levels Recently reported clinical data ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Exe...

The shares of clinical-stage genetic medicine company, Wave Life Sciences (NASDAQ:WVE +29.6%) have recorded the best intraday gain in more than a year on Monday in reaction to favorable early-stage data for WVE-004, an experimental therapy for amyotrophic lateral sclerosis and frontotemporal ...

Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment groups after single doses Extending dose observation period from three months (day 85) to six months to identify the maximum reduction of poly(GP) and duration of effect o...

Gainers: SPI Energy (SPI) +36%. Workday (WDAY) +11%. TMC the metals company (TMC) +10%. ThredUp (TDUP) +7%. WAVE Life Sciences (WVE) +4%. Losers: CRISPR Therapeutics (CRSP) -7%. ImmunoGen (IMGN) -5%. Ionis Pharmaceuticals (IONS) -5%. Radius Health (RDUS) -5%. Fluidigm (FLDM) -4%. ...

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Exe...